Itamar™ Medical Announces First Quarter 2020 Preliminary Revenue Increase of Approximately 40%

NEXT STORY
Quantum Materials Announces QDX™ HealthID to Support Back-to-Work “Immunization Passport” Programs
PREV STORY
Alimera Sciences Pre-Announces Expected Top Line Revenue for Q1 2020 and Provides COVID-19 Business Update
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Rozlytrek, Roche’s first tumour-agnostic therapy, approved in Europe for people with NTRK fusion-positive solid tumours and for people with ROS1-positive advanced non-small cell lung cancer

author_avatar
NASDAQ Market News

Immuron’s Travelan® Sales Continue to Soar in Third Quarter of FY2018 in Australian & US Markets

author_avatar
NASDAQ Market News

Inventiva announces the design of LEGEND, a Phase IIa combination trial with lanifibranor and SGLT2 inhibitor empagliflozin in patients with NASH and type 2 diabetes

author_avatar
NASDAQ Market News